CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.

Eli Lilly LLY and AbbVie ABBV are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

In 2008, CVS Caremark, a prescription benefit management company, signed on to use Microsoft's HealthVault. ... Lilly hit as PBM drops Zepbound, but retains Wegovy.

Zepbound growth has outpaced Wegovy in recent months, and sales quadrupled to $2.31 billion in the first three months of this year compared to the same period of 2024, while Mounjaro more than ...